Is Amprius Utilized Sciences Stock A Buy?

Roth Capital Markets analyst Chip Moore raised his 12-month price objective on Amprius Utilized sciences (Amprius Utilized sciences Stock Quote, Chart, Info, Analysts, Financials NYSE:AMPX) to US$14 from US$10 whereas sustaining a “Buy” rating in an Oct. 22 report, citing continued enterprise momentum, rising demand for its high-energy-density battery choices, and prudent functionality development.

“We like administration’s prudent technique to scale up, whereas we anticipate demand for the company’s principal energy-density choices to develop significantly inside the coming years, with sizable capital-light functionality already in place,” Moore talked about.

Amprius is anticipated to launch its third-quarter ends in early November, with Roth projecting earnings of US$15.9-million and Adjusted EBITDA of –US$4.6-million, reflecting sequential product sales growth and a second straight quarter of optimistic gross margins pushed by the SiCore platform. Moore cautioned that outcomes may keep “lumpy” due to the early stage of commercialization nevertheless talked about key milestones and purchaser adoption are the additional important indicators of progress.

He well-known that SiCore batteries proceed to understand traction, supported by a US$35-million purchase order from a repeat drone purchaser in mid-September, following an earlier US$15-million order this 12 months. On Oct. 14, Amprius launched a model new win with Empirical Strategies Aerospace (ESAero) for use of its high-power SiCore SA08 cells in UAVs after worthwhile qualification. European drone producer Nordic Wing moreover chosen the company’s SiCore cells to power its ASTERO ISR fixed-wing UAV.

Amprius moreover named Ricardo Rodriguez as chief financial officer on Oct. 6, ending a deliberate transition following the retirement of Sandra Wallach. Moore talked about he views the appointment positively as the company enters “the next part of its evolution,” having achieved optimistic gross margins last quarter amid accelerating enterprise momentum.

On the end of Q2 2025, Amprius had shipped to 93 shoppers (along with 43 new ones) all through 86% of product sales exterior the U.S., with remaining effectivity obligations of roughly US$29.1-million. Cash stood at US$54.2-million, with no debt and about US$47.6-million obtainable beneath its at-the-market offering. The company may also be investing in a ten MWh pilot-scale electrode manufacturing line in Fremont, supported by a US$10.5-million U.S. Safety Innovation Unit contract, to extra qualify its drone-grade utilized sciences.

Moore talked about Amprius must generate US$64.3-million in earnings and –US$19.2-million in Adjusted EBITDA in fiscal 2025, enhancing to US$145.8-million in earnings and –US$2.2-million in fiscal 2026.

Roth’s new US$14 objective depends on an 11.5× a lot of of projected 2026 product sales, up from 8× beforehand.

“Whereas further unstable on the current scale, we proceed to see sturdy potential for aggressive growth merchants,” Moore talked about, together with that Amprius’s experience and positioning in defence and aerospace battery markets “keep compelling.”

-30-